PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).

被引：0
|
作者：
Duan, P. [1 ]
Zhao, P. [2 ]
Zhang, L. [2 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] US FDA, Off Clin Pharmacol, Off Translat Sci, CDER, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT-17
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [1] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)
    Peng Duan
    Ping Zhao
    Lei Zhang
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 689 - 705
  • [2] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)
    Duan, Peng
    Zhao, Ping
    Zhang, Lei
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (04) : 689 - 705
  • [3] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)
    Chiney, M. S.
    Polepally, A. R.
    Nader, A. M.
    Dufek, M. B.
    Klein, C. E.
    Ng, J. W.
    Shebley, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
  • [4] QUALIFICATION AND APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATION (MANDS) TO PREDICT DRUG-DRUG INTERACTIONS FOR ALISERTIB
    Patel, C.
    Ananthula, H.
    Zhou, X.
    Xia, C.
    Chowdhury, S.
    Zhu, A.
    Pusalkar, S.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S82 - S82
  • [5] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
    de Kanter, Ruben
    Sidharta, Patricia N.
    Delahaye, Stphane
    Gnerre, Carmela
    Segrestaa, Jerome
    Buchmann, Stephan
    Kohl, Christopher
    Treiber, Alexander
    CLINICAL PHARMACOKINETICS, 2016, 55 (03) : 369 - 380
  • [6] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ATORVASTATIN AND RELATED SPECIES AND PREDICTION OF DRUG-DRUG INTERACTIONS IN HUMANS.
    Morse, B. L.
    Alberts, J. J.
    Kolur, A.
    Posada, M. M.
    Tham, L.
    Loghin, C.
    Hall, S. D.
    Dickinson, G. L.
    Hillgren, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S63 - S64
  • [7] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE DRUG-DRUG INTERACTION (DDI) RISK OF ALECTINIB.
    Cleary, Y.
    Gertz, M.
    Morcos, P. N.
    Youdim, K.
    Fowler, S.
    Yu, L.
    Sekiguchi, N.
    Takanashi, K.
    Kaneko, A.
    Phipps, A.
    Parrott, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S40 - S40
  • [8] Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites
    Zhang, Tao
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 : 216 - 229
  • [9] Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir
    Stader, Felix
    Battegay, Manuel
    Marzolini, Catia
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1231 - 1239
  • [10] Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults
    Sia, Jie En Valerie
    Lai, Xuan
    Wu, Xinyi
    Zhang, Fan
    Li, Haiyan
    Cui, Cheng
    Liu, Dongyang
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 182
12345